RxDoctor Payments Data

Christopher Centafont, DO

Cardiovascular Disease · Dothan, ALNPI 1447239595

Payments from drug & device makers

$4,080in general payments, 2019–2025

Across 233 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$571
  • Pfizer$436
  • Esperion Therapeutics, Inc.$402
  • Amgen$353
  • Amarin Pharma, Inc.$339
  • Boston Scientific$300
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,080100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,080 in reported general payments places this provider in the 55th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$810,691
Medicare patients
1,428
Services billed
10,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban899$868,310
EntrestoSacubitril/Valsartan444$503,252
XareltoRivaroxaban155$123,914
Repatha SureclickEvolocumab99$85,012
BrilintaTicagrelor86$61,927
Ranolazine ErRanolazine223$29,932
JardianceEmpagliflozin12$19,335
Metoprolol Succinate1,158$18,103
VascepaIcosapent Ethyl32$17,824
Nifedipine ErNifedipine515$17,142
Isosorbide Mononitrate ErIsosorbide Mononitrate834$16,358
Atorvastatin Calcium1,322$14,991
Midodrine Hcl106$13,481
Bumetanide240$9,086
Losartan Potassium644$8,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$436$868,310899 claims
NovartisEntresto$228$503,252444 claims
Johnson & JohnsonXarelto$63$123,914155 claims
AstraZenecaBrilinta$571$61,92786 claims
Boehringer IngelheimJardiance$118$19,33512 claims
Kowa Pharmaceuticals America, Inc.Livalo$41$8,34916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →